IXICO plc (AIM: IXI) is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI‑driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the company has built a global reputation and 20‑year track record as an end‑to‑end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech, disease consortia and non‑profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.

The IXICO Platform is tailor‑made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases su...